

Attorney Docket No.: WSTR-0014C
Inventors: Shiekhattar, Ramin
Serial No.: 10/634,574
Filing Date: August 5, 2003
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-3 (canceled).

Claim 4 (currently amended): A method for identifying an agent that modulates the ubiquitin E3 ligase activity or ubiquitin hydrolase activity of a BRCA1-BRCA2-containing complex (BRCC) ~~BRCC~~ comprising contacting BRCC with a test agent and monitoring the ability of said agent to alter the level of ubiquitination of select protein which is indicative of ubiquitin E3 ligase activity or ubiquitin hydrolase activity of BRCC, wherein said BRCC is a multi-protein complex that consists of BRCA2, BRCA1, and RAD51, as well as one or more proteins selected from the group consisting of BRAD1, BRCC300, BRCC140, BRCC130, BRCA1 Δ11, BRCC80, BRE, and BRCC36.

Claim 5 (currently amended): A method for identifying an agent that modulates the DNA repair activity of a BRCA1-BRCA2-containing complex (BRCC) ~~BRCC~~ comprising contacting a cell containing BRCC with a test agent and monitoring the ability of said agent to alter cell survival rates in the presence of ionizing radiation or alter homology-directed DNA repair which is indicative of DNA repair activity of BRCC, wherein said BRCC is a multi-protein complex that consists of BRCA2, BRCA1, and RAD51, as well as one more proteins selected from the group consisting

Attorney Docket No.: WSTR-0014C
Inventors: Shiekhattar, Ramin
Serial No.: 10/634,574
Filing Date: August 5, 2003
Page 3

of BRAD1, BRCC300, BRCC140, BRCC130, BRCA1 Δ11, BRCC80, BRE, and BRCC36.

Claim 6 (currently amended): A method for identifying an agent that modulates the transcriptional regulator activity of a BRCA1-BRCA2-containing complex (BRCC) ~~BRCC~~ comprising contacting a cell containing BRCC with a test agent and monitoring the ability of said agent to alter the expression of genes containing p53 response elements which is indicative of transcriptional regulator activity of BRCC, wherein said BRCC is a multi-protein complex that consists of BRCA2, BRCA1, and RAD51, as well as one or more proteins selected from the group consisting of BRAD1, BRCC300, BRCC140, BRCC130, BRCA1 Δ11, BRCC80, BRE, and BRCC36.

Claims 7-12 (canceled).

Claim 13 (currently amended): A method for identifying an agent that inhibits the expression of BRCC36 or BRE protein comprising contacting a cell expressing BRCC36 or BRE protein with a test agent and monitoring the ability of said agent to alter the expression of RBCC36 or BRE protein, wherein said test agent is selected from the group consisting of an antisense molecule, a siRNA molecule, or a RNAi molecule or ribozymes targeted to nucleic acid sequences encoding BRCC36 or BRE.

Claims 14-17.